Over the last 7 days, the United States market has dropped 4.4%, yet it remains up by 7.5% over the past year, with earnings projected to grow by 14% annually. In this context of fluctuating performance and optimistic earnings forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to changing market dynamics.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 242 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Rezolve AI

Simply Wall St Growth Rating: ★★★★★☆

Overview: Rezolve AI Limited offers artificial intelligence solutions for the commerce sector and has a market capitalization of $332.05 million.

Operations: Rezolve AI Limited generates revenue primarily from its Internet Software & Services segment, amounting to $0.15 million.

Rezolve AI, with a forecasted annual revenue growth of 45%, is outpacing the U.S. market average of 8.4%, signaling robust potential in high-growth tech sectors. Despite its current unprofitability and shareholder dilution over the past year, the company's strategic initiatives, including a $1 billion Bitcoin treasury to support its upcoming AI-driven crypto payment platform, highlight its innovative approach to integrating AI and blockchain technologies. This bold move not only secures Rezolve AI's financial position but also aligns it with future digital economy trends, potentially revolutionizing global commerce through enhanced payment solutions and cryptocurrency integration.

• Take a closer look at Rezolve AI's potential here in our health report.

• Learn about Rezolve AI's historical performance.

Blueprint Medicines

Simply Wall St Growth Rating: ★★★★★★

Overview: Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, with a market cap of $5.61 billion.

Operations: The company generates revenue from its pharmaceuticals segment, totaling $508.82 million.

Blueprint Medicines, amid a challenging landscape for biotech innovation, is making notable strides with a forecasted annual revenue growth of 22.4%, outpacing the U.S. market average of 8.3%. Despite being currently unprofitable, the company's robust pipeline and recent positive trial results for AYVAKIT® suggest potential future profitability, underscored by an impressive projected return on equity of 48.3% in three years' time. The firm's strategic focus on mast cell-driven diseases and advanced systemic mastocytosis treatments was highlighted at the recent AAAAI/WAO Joint Congress, demonstrating its commitment to addressing unmet medical needs through high-potential R&D investments totaling $508 million last year—a significant figure that underscores its dedication to innovation in biotechnology.

• Delve into the full analysis health report here for a deeper understanding of Blueprint Medicines.

• Understand Blueprint Medicines' track record by examining our Past report.

CyberArk Software

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CyberArk Software Ltd. is a company that develops, markets, and sells software-based identity security solutions and services globally, with a market cap of $16.70 billion.

Operations: CyberArk Software Ltd. generates revenue primarily through its security software and services segment, which accounted for approximately $1 billion. The company operates across various regions, including the United States, Europe, the Middle East, and Africa.

CyberArk Software, amidst a transformative tech landscape, has recently filed for a significant Shelf Registration and announced innovative collaborations that underscore its strategic focus on cybersecurity in the IoT and operational technology sectors. These initiatives are pivotal as CyberArk's revenue is forecasted to grow at 17.7% annually, outpacing the US market average of 8.4%. Despite current unprofitability, earnings are expected to surge by 47.23% annually over the next three years. The company's recent product launches and partnerships, such as with Device Authority for enhancing enterprise application security through Zero Trust principles, highlight its commitment to addressing critical cybersecurity challenges in increasingly digitized industries. This approach not only positions CyberArk at the forefront of high-growth tech but also aligns with industry needs for robust digital defense mechanisms in an era where cyber threats are escalating rapidly.

• Get an in-depth perspective on CyberArk Software's performance by reading our health report here.

• Gain insights into CyberArk Software's past trends and performance with our Past report.

Make It Happen

• Get an in-depth perspective on all 242 US High Growth Tech and AI Stocks by using our screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:RZLV NasdaqGS:BPMC and NasdaqGS:CYBR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com